Values First Advisors Inc. Acquires 3,655 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Values First Advisors Inc. lifted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 277.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,970 shares of the biotechnology company’s stock after buying an additional 3,655 shares during the quarter. Values First Advisors Inc.’s holdings in Blueprint Medicines were worth $433,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Wellington Management Group LLP increased its stake in Blueprint Medicines by 22.5% in the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock worth $366,726,000 after purchasing an additional 729,055 shares during the period. State Street Corp increased its stake in Blueprint Medicines by 16.2% in the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after buying an additional 385,818 shares during the period. Geode Capital Management LLC lifted its holdings in Blueprint Medicines by 1.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company’s stock valued at $136,942,000 after buying an additional 20,703 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Blueprint Medicines by 9.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 597,232 shares of the biotechnology company’s stock valued at $55,244,000 after buying an additional 50,736 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its stake in Blueprint Medicines by 161.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock worth $45,888,000 after acquiring an additional 306,079 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BPMC shares. Piper Sandler lifted their price target on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research report on Wednesday, January 15th. Stephens reissued an “overweight” rating and set a $140.00 price target on shares of Blueprint Medicines in a research report on Thursday, January 2nd. HC Wainwright restated a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, November 15th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines currently has an average rating of “Moderate Buy” and an average price target of $123.72.

Blueprint Medicines Stock Performance

Shares of BPMC opened at $103.56 on Thursday. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The firm has a market cap of $6.58 billion, a PE ratio of -49.08 and a beta of 0.62. Blueprint Medicines Co. has a 12 month low of $72.24 and a 12 month high of $121.90. The stock has a fifty day moving average price of $99.65 and a 200-day moving average price of $94.77.

Insider Activity at Blueprint Medicines

In other news, Director Jeffrey W. Albers sold 15,000 shares of the business’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the sale, the director now owns 157,557 shares in the company, valued at approximately $14,143,891.89. The trade was a 8.69 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total transaction of $216,257.40. Following the completion of the transaction, the chief operating officer now directly owns 71,657 shares of the company’s stock, valued at $6,814,580.70. The trade was a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 49,851 shares of company stock valued at $4,984,696 in the last ninety days. Corporate insiders own 4.21% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.